First-pass extracted concept

prime editors

Candidate: concept label3 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Prime editors are identified as a genome editing modality highlighted by the review. The abstract places them among advances expanding therapeutic possibilities beyond gene knockout.

Source 1DOI PubMed

Prime editors are described as part of the expanded CRISPR toolkit. The abstract associates them with enabling a wider array of genetic alterations.

Source 3DOI PubMed

What problem it solves

The review frames prime editors as helping extend CRISPR therapeutics beyond traditional knockout strategies.

Source 1DOI PubMed

Evidence Snippets

advances in genome editing technologies, ranging from CRISPR-Cas nucleases to base and prime editors

Evidence 1Source 1DOI PubMedprovenance

This review provides an introduction to the state-of-the-art gene editing tools-including ZFNs, TALENs, CRISPR/Cas9 systems, base editors, and prime editors-and evaluates their application in lipid metabolic pathways central to CVD pathogenesis.

Evidence 2Source 2DOI PubMedprovenance

Progress in CRISPR tools-CRISPR nucleases, base editors and prime editors-has expanded the toolkit to induce targeted insertions or deletions, nucleotide conversions and a wider array of genetic alterations.

Evidence 3Source 3DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Source 2primary paper2026MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 3primary paper2025MEDDOI PubMed

1 evidence snippet 2 linked claims Claim 1 Claim 2

Linked Claims

Claim 1capability expansionsupports2026Source 1DOI PubMed

Advances in CRISPR-Cas nucleases, base editors, and prime editors are expanding the therapeutic landscape beyond traditional gene knockout approaches.

Claim 2scope summarysupports2026Source 2DOI PubMed

The review covers state-of-the-art gene editing tool classes including ZFNs, TALENs, CRISPR/Cas9 systems, base editors, and prime editors for applications in lipid metabolic pathways relevant to cardiovascular disease.

Quoted textsource-backed

This review provides an introduction to the state-of-the-art gene editing tools-including ZFNs, TALENs, CRISPR/Cas9 systems, base editors, and prime editors-and evaluates their application in lipid metabolic pathways central to CVD pathogenesis.

Claim 3translation considerationsupports2026Source 1DOI PubMed

Delivery challenges, long-term safety, immune responses, and editing specificity are critical considerations for safe and effective integration of CRISPR technologies into medicine.

Claim 4application scopesupports2025Source 3DOI PubMed

AI contributes to refining nuclease-based editing, base editing, and prime editing.

Quoted textsource-backed

We highlight how AI contributes to refining nuclease-based editing, base editing and prime editing.

Claim 5problem statementsupports2025Source 3DOI PubMed

Variations in editing outcomes across cell types and unintended off-target effects remain substantial hurdles for CRISPR tools.

Quoted textsource-backed

Nevertheless, variations in editing outcomes across cell types and unintended off-target effects still present substantial hurdles.